Browsing by Author "Mousdicas, Nico"

Now showing 1 - 6 of 6
  • Thumbnail Image
    Item
    Clinical correlations of recent developments in the pathogenesis of atopic dermatitis
    (Scielo, 2008-02) Sehra, Sarita; Holbreich, Mark; Kaplan, Mark H.; Tuana, Florencia M. Barbé; Mousdicas, Nico; Travers, Jeffrey B.; Pediatrics, School of Medicine
    Atopic dermatitis is a chronic inflammatory skin disease with a steadily increasing prevalence affecting 10-20 of infants and 1-3 of adults globally. It is often the first clinical manifestation of atopic disease preceding asthma and allergic rhinitis. Probably half of the children with atopic dermatitis develop some other form of atopic disease later in life. The pathogenesis involves a complex interplay of factors including genetic predisposition due to altered immune or skin barrier function, interactions with the environment such as food and allergen exposures, and infectious triggers of inflammation. In this review, we summarize the recent advances in understanding the contribution of different factors in the pathophysiology of atopic dermatitis and how insights provide new therapeutic potential for its treatment.
  • Thumbnail Image
    Item
    Eruptive Disseminated Porokeratosis Associated with Corticosteroid-Induced Immunosuppression
    (Wiley, 2015-10) Bednarek, Robert; Ezra, Navid; Toubin, Yulianna; Linos, Konstantinos; Mousdicas, Nico; Department of Dermatology, IU School of Medicine
    Eruptive disseminated porokeratosis (EDP) is a disease that presents clinically with sudden onset of erythematous papules and plaques, with a ridge-like border histologically represented by a cornoid lamella. We report a case of EDP occurring in a 39-year-old woman 3 days after completion of a 2-week course of oral corticosteroid therapy for an acute asthma exacerbation. The patient was treated with emollients and sun protection. Unlike the more chronic disseminated superficial (actinic) porokeratosis, EDP secondary to immunosuppression from corticosteroid therapy has very rarely been reported in the dermatological literature.
  • Thumbnail Image
    Item
    Fibroblast Senescence and Squamous Cell Carcinoma: How wounding therapies could be protective
    (Wolters Kluwer, 2013) Travers, Jeffrey B.; Spandau, Dan F.; Lewis, Davina A.; Machado, Christiane; Kingsley, Melanie; Mousdicas, Nico; Somani, Ally-Khan; Dermatology, School of Medicine
    Background: Squamous cell carcinoma (SCC), which has one of the highest incidences of all cancers in the United States, is an age-dependent disease, with the majority of these cancers diagnosed in people age 70 and older. Recent findings have led to a new hypothesis on the pathogenesis of SCC. Objectives: To evaluate the potential of preventive therapies to reduce the incidence of SCC in at-risk geriatric patients. Materials and methods: Survey of current literature on wounding therapies to prevent SCCs. Results: This new hypothesis of SCC photocarcinogenesis states that senescent fibroblasts accumulate in the dermis, resulting in a reduction in dermal insulin-like growth factor-1 (IGF-1) expression. This lack of IGF-1 expression sensitizes epidermal keratinocytes to fail to suppress ultraviolet light B (UVB)-induced mutations, leading to increased proclivity to photocarcinogenesis. Recent evidence suggests that dermal wounding therapies, specifically dermabrasion and fractionated laser resurfacing, can decrease the proportion of senescent dermal fibroblasts, increase dermal IGF-1 expression, and correct the inappropriate UVB response found in geriatric skin, protecting geriatric keratinocytes from UVB-induced SCC initiation. Conclusions: In this review, we will discuss the translation of pioneering basic science results implicating commonly used dermal fibroblast rejuvenation procedures as preventative treatments for SCC.
  • Thumbnail Image
    Item
    Pediatric positional sitting dermatitis: a new form of pediatric contact dermatitis
    (Wiley, 2016-05) Isaacs, Michael J.; Strausburg, Matthew B.; Mousdicas, Nico; Department of Dermatology, IU School of Medicine
    We report on four pediatric patients who presented with localized dermatitis in areas subject to repetitive friction due to their sitting positions. We propose that the cause of the eruption was irritant contact dermatitis due to frequently sitting in a crossed-leg sitting position, an entity for which we have coined the term pediatric positional sitting dermatitis (PPSD). The goal of this report is to raise clinicians' awareness of PPSD, which to our knowledge has not been previously described, and to discuss management of these patients.
  • Thumbnail Image
    Item
    Rosacea Fulminans Precipitated by Acute Stress: A Case Report Describing an Integrative Approach for a Patient Reluctant to Use Isotretinoin
    (InnoVision Health Media, 2016-12) Veerkamp, Patrick; Mousdicas, Nico; Bednarek, Robert; Department of Dermatology, IU School of Medicine
    CONTEXT: Rosacea fulminans is a rare skin disorder with a multifactorial etiology. Stress is one of the common precipitating factors of this condition but is not often targeted in treatment. Isotretinoin is considered part of the first-line therapy for this condition but, in cases where its use is restricted, other therapeutic interventions as part of an integrative approach may be effective. PATIENT CONCERNS: A 38-y-old female presented with rosacea fulminans brought on by an acutely stressful event. After multiple failed therapies, she experienced resolution of her symptoms with a combination of systemic corticosteroids, antibiotics, diet modification, and stress reduction, with the treatment of stress playing a significant role. CONCLUSIONS: Stress management and diet modification are key adjunctive therapies in the treatment of rosacea fulminans and need to be addressed more often in treatment. In cases where patients are reluctant or unable to take isotretinoin, an integrative approach may be effective in achieving symptomatic improvement.
  • Thumbnail Image
    Item
    Treatment of estrogen-induced dermatitis with omalizumab
    (Elsevier, 2019-05-25) Ocana, Jesus A.; Bell, Maria C.; Heskett, Jordan B.; Baker, William H.; Mousdicas, Nico; Turner, Matthew J.; Dermatology, IU School of Medicine
    In 1945, Drs Bernhard Zondek and Yehuda Bromberg demonstrated intradermal treatment with estrone and estradiol benzoate induced urticarial lesions in some patients.1 Fifty years later, Shelley et al,2 who introduced the concept of progesterone dermatitis several decades prior, defined estrogen dermatitis based on studies of 7 women with premenstrual flares of skin eruptions including papulovesicular, urticarial, or eczematous lesions or generalized pruritus. Previously described therapies for estrogen dermatitis include estrogen desensitization, tamoxifen, leuprolide, and oophorectomy.3 Here we report a case of estrogen-induced dermatitis successfully treated with omalizumab.